Skip to content
New issue

Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community.

By clicking “Sign up for GitHub”, you agree to our terms of service and privacy statement. We’ll occasionally send you account related emails.

Already on GitHub? Sign in to your account

Fluvoxamine and theophylline PBPK models #292

HannahBri opened this Issue Mar 4, 2019 · 2 comments


None yet
3 participants
Copy link

HannahBri commented Mar 4, 2019

Dear all,

We have been working on models for DDI prediction, building a small network of interacting CYP1A2 perpetrator and victim drugs. Two whole-body PBPK models of fluvoxamine and theophylline were carefully developed and then evaluated by prediction of clinical DDI studies.

The corresponding manuscript, including comprehensive documentation, has been published online in CPT: PSP and the models as well as PK-Sim projects presenting the predicted DDI studies have been uploaded as Open Systems Pharmacology repositories to GitHub.

Related publication:
Britz H, Hanke N, Volz AK, Spigset O, Schwab M, Eissing T, Wendl T, Frechen S, Lehr T.
PBPK models for CYP1A2 DDI prediction: a modelling network of fluvoxamine, theophylline, caffeine, rifampicin and midazolam. CPT Pharmacometrics Syst Pharmacol 2019.

All models can be found here.

Best regards,


This comment has been minimized.

Copy link

sfrechen commented Mar 5, 2019

Great work, Hannah! Thank you for sharing!


This comment has been minimized.

Copy link

regulus92 commented Mar 13, 2019

Something learned. Thank you for sharing!

Sign up for free to join this conversation on GitHub. Already have an account? Sign in to comment
You can’t perform that action at this time.